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RESEARCH ARTICLE
Drug Synergy Drives Conserved Pathways to
Increase Fission Yeast Lifespan
Xinhe Huang1¤*, Markos Leggas2, Robert C. Dickson1*
1 Department of Molecular and Cellular Biochemistry and the Lucille Markey Cancer Center, University of
Kentucky College of Medicine, Lexington, Kentucky, United States of America, 2 Department of
Pharmaceutical Sciences and the Lucille Markey Cancer Center, College of Pharmacy, University of
Kentucky, Lexington, Kentucky, United States of America
¤ Current Address: School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China
* bobd@uky.edu (RCD); 2196000@qq.com (XH)
Abstract
Aging occurs over time with gradual and progressive loss of physiological function. Strate-
gies to reduce the rate of functional loss and mitigate the subsequent onset of deadly age-
related diseases are being sought. We demonstrated previously that a combination of rapa-
mycin and myriocin reduces age-related functional loss in the Baker’s yeast Saccharomy-
ces cerevisiae and produces a synergistic increase in lifespan. Here we show that the same
drug combination also produces a synergistic increase in the lifespan of the fission yeast
Schizosaccharomyces pombe and does so by controlling signal transduction pathways
conserved across a wide evolutionary time span ranging from yeasts to mammals. Path-
ways include the target of rapamycin complex 1 (TORC1) protein kinase, the protein kinase
A (PKA) and a stress response pathway, which in fission yeasts contains the Sty1 protein
kinase, an ortholog of the mammalian p38 MAP kinase, a type of Stress Activated Protein
Kinase (SAPK). These results along with previous studies in S. cerevisiae support the prem-
ise that the combination of rapamycin and myriocin enhances lifespan by regulating signal-
ing pathways that couple nutrient and environmental conditions to cellular processes that
fine-tune growth and stress protection in ways that foster long term survival. The molecular
mechanisms for fine-tuning are probably species-specific, but since they are driven by con-
served nutrient and stress sensing pathways, the drug combination may enhance survival
in other organisms.
Introduction
Most organisms show signs of aging, characterized by the gradual but progressive loss of physi-
ological functions over time. As humans enter their fifties and sixties the consequences of such
functional losses manifest as increased incidence of cancer, type 2 diabetes, neurodegeneration,
cardiovascular disease and immune dysfunction, the age-related diseases. Current research
seeks to reduce the incidence and severity of these diseases to improve health in the elderly.
One promising avenue of research centers on the target of rapamycin complex 1 (TORC1)
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protein kinase [1–3]. TORC1 is a central regulator of aging and longevity, since down-regulat-
ing its activity by treatment with the natural product rapamycin or related synthetic com-
pounds, reduces signs of aging and extends lifespan in model organisms ranging from yeast to
mice [4–8]. These seminal results have spawned an array of TOR-related research including
work from our laboratory which identified a strategy that produces a synergistic increase in the
chronological lifespan (CLS) of the Baker’s yeast Saccharomyces cerevisiae [9]. This being the
first example of a true synergistic increase in lifespan produced by drugs. Our strategy uses a
low dose of rapamycin to lower (not inhibit) TORC1 activity and another natural product,
myriocin, to lower (not inhibit) the activity of serine palmitoyltransferase (SPT), the first en-
zyme in the sphingolipid biosynthesis pathway. The conserved nature of TORC1 and SPT in
eukaryotes suggested that the combination drug treatment (ComboDT) might enhance life-
span in other eukaryotes. Here we verify this prediction by using the fission yeast Schizosac-
charomyces pombe, a distant and divergent relative of budding yeast.
Most eukaryotes have two TOR complexes with TORC1 primarily responsible for sensing
nutrients, stresses, growth factors, and energy status and coupling these to growth and survival
including lifespan whereas TORC2 responds to growth factors and controls cytoskeletal func-
tions but has no known role in lifespan [1, 2, 10]. Rapamycin primarily inhibits TORC1 and at
high doses it inhibits growth. However, it does effect TORC2 in some organisms such as mam-
mals [1]. Rapamycin does not inhibit growth in fission yeasts probably because of incomplete
inhibition of TORC1 activity, but combining rapamycin with caffeine completely inhibits en-
zyme activity and growth [11]. Despite incomplete inhibition of TORC1, rapamycin treatment
extends CLS in fission yeast as does treatment with caffeine [12], similar to the effect of caffeine
on budding yeast [13]. In contrast to ComboDT, rapamycin and caffeine in combination are
no more effective in increasing fission yeast lifespan CLS than are the single drugs.
Sphingolipids have many functions in eukaryotes including roles in age-related human dis-
eases [14–17]. In S. cerevisiae they can be modulated to increase both CLS, a measure of surviv-
al in non-dividing cells, and replicative lifespan (RLS), a measure of how many times a cell can
divide [reviewed in [18]]. For example, treatment with a low dose of myriocin to reduce SPT
activity increases CLS in S. cerevisiae [19] and treatment with even lower doses of myriocin in
combination with low doses of rapamycin produce a synergistic increase in CLS [9]. It is not
clear how such modulation of sphingolipids increases CLS or RLS, but it is likely to be complex
and involve changes in sphingolipids that act as second messengers as well as effects on cellular
processes connected to membranes including membrane trafficking and the functionality of
membrane-bound proteins.
What we do know is that myriocin and ComboDT increase budding yeast CLS by controlling
conserved nutrient sensing and stress response signaling pathways including, besides TORC1,
the protein kinase A (PKA) and AMP kinase (AMPK) pathways [9, 19]. In addition, we know
that myriocin [20] and ComboDT (unpublished data) modulate gene expression and cellular
processes (GO terms) in ways that are similar to what is found with rapamycin treatment and di-
etary or calorie restriction (CR), the gold standards for slowing aging and enhancing lifespan.
With this information along with current knowledge of S. pombe aging and lifespan as back-
ground, we examined the effect of ComboDT on fission yeast and show that the drugs enhance
CLS and do so in a genuinely synergistic fashion. As predicted, the drug combination enhances
CLS by using signaling pathways with known roles in aging and lifespan. These include the
TORC1 pathway [12] and its downstream protein kinase substrates [21–24], the nutrient-sens-
ing PKA pathway [21] and the Sty1 stress response pathway, [24, 25]. Sty1 is the fission yeast
ortholog of the Hog1 kinase of S. cerevisiae, which controls responses to osmotic stress [re-
viewed in [26, 27]]. Sty1 is also an ortholog of the mammalian p38 MAP kinase, a Stress Acti-
vated Protein Kinase (SAPK) with strategic roles in inflammation and stress responses and
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more recently discovered roles in cell cycle regulation, proliferation and senescence [reviewed
in [28]].
One of the TORC1 substrates with well documented roles in aging and lifespan is the con-
served S6 kinase, prime examples being Sch9 in S. cerevisiae [29, 30] and S6K1 and S6K2 in
mammals [31, 32]. The S6 kinase orthologs in fission yeasts appear to be Psk1, Sck1 and Sck2
[33]. We find that all of these kinases are involved in CLS enhancement by ComboDT. Togeth-
er, our results support the premise that ComboDT enhances lifespan by controlling signaling
pathways which regulate conserved cellular processes in ways that have evolved to meet spe-
cies-specific needs for long term survival.
Results
For culture medium we used yeast extract plus supplements (YES) in our studies as it is used
most often for assaying CLS in fission yeast [12, 22–24]. While 3% glucose is often used for cul-
turing fission yeasts, we used 2% because it reduces adaptive regrowth in fission yeasts [21] and
is used extensively in studies of budding yeast lifespan [34]. Preliminary dose response studies
showed that neither myriocin nor rapamycin impaired the cell density achieved at 48 hrs of
growth (S1A and S1B Fig.), the time at which CLS assays were initiated. Likewise, the concen-
tration of drugs used in ComboDT (150 nM or 60 ng/ml myriocin and 50 nM or 46 ng/ml
rapamycin) did not interfere with cell density at 48 hrs (S2 Fig.) and, in fact, cells treated with
myriocin or ComboDT grew to a slightly higher density than without drug treatment, similar
to what we have observed in budding yeasts [9, 19]
Synergistic increase in lifespan
To determine if ComboDT can produce a synergistic increase in S. pombe CLS, we searched for
low concentrations of each drug showing little or no effect on lifespan but that produced a large
and potentially synergistic increase in lifespan when used in combination. An example of the ef-
fect of one such combination on cell survival is shown in Fig. 1A. To assess whether the increase
in CLS produced by this combination of drugs is synergistic, we performed survival experiments
similar in design to those used to develop drug combinations that produce a synergistic decrease
in the viability of cancer cells. Survival was measured after growing cells to stationary phase (48
hrs, CLS day 1) and then again after 32 hrs of incubation, since at this time viability in untreated
cells had decreased by 90% allowing enhancement caused by the ComboDT to be evaluated over
a large concentration range (Table 1, S3A and S3B Fig., for dose response plots).
The effect of myriocin and rapamycin alone on survival was assessed to obtain the median
effective concentrations (EC50) for each drug. The EC50 of rapamycin was 221 nM and for
myriocin it was 231 nM. Non-linear regression was used to fit the survival verses concentration
data (S3A and S3B Fig.) and the resulting curves were used to determine the concentrations
that would be required for each drug alone to elicit the same survival effect as observed with
combinations of rapamycin and myriocin in different molar ratios (Table 1). These data were
used to calculate the combination index (CI) according to Chou and Talalay [35]. To determine
how robust the CI results were, we calculated the alpha and beta4 parameters used to determine
deviation from additivity in the more restrictive models of Greco and Plummer, respectively
[36, 37]. All mathematical models predict synergy (Table 1). Surprisingly, the molar ratio of
the two drugs has no effect on synergy whereas their concentration does. The effect approaches
additivity as the rapamycin concentration approaches 400 nM and myriocin approaches
100 nM. Conversely, concentrations of 100 nM rapamycin and 300 nMmyriocin approach ad-
ditivity. Below those concentrations, for both drugs, there is strong synergy and above those
concentrations, for both drugs, there is antagonism (Table 1, underlined values).
Drug Synergy Increases Lifespan
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Improved stress resistance is associated with increased lifespan in many organisms [38, 39].
This correlation was first observed in fission yeast carrying mutations in nutrient signaling
pathways [21] and recently in cells treated with rapamycin or caffeine or both to inhibit
Fig 1. ComboDT increases lifespan and stress resistance. (A) Viability for 972 h- cells is shown for values normalized to CLS day 1 (48 hrs of incubation
at 30°). Data are the mean ± SEM of viable cells in triplicate cultures in these and all other lifespan data sets. The dashed line represents the small
enhancement in viability for the single drugs values added to the WT value at each time point. Values for statistical significance are given in S2 Table. (B) The
spot-dilution (10-fold from left to right) assays in the upper panel show the response of cells on CLS day 1 to heat or hydrogen peroxide stress while the lower
panel shows heat stress resistance at each day of the CLS assay.
doi:10.1371/journal.pone.0121877.g001
Table 1. Myriocin and rapamycin generate a synergistic increase in lifespan.
Combination Treatment
Concentration (nM)
Single Treatment
Concentrations (nM) †
Synergy is defined as: Molar ratio
Rap Myr Rap Myr Survival (fold over control)¶ CI < 1Chou α > 0 Greco β4 > 0 Plummer Myr/Rap
50 15 251 90.3 2.33 0.366 28.4 3.485 0.3
100 30 332 102 2.67 0.597 5.51 1.351 0.3
200 60 2180 130 3.44 0.555 4.41 2.161 0.3
400 120 2180 196 5 0.795 0.62 0.612 0.3
50 50 2180 203 5.11 0.27 43.3 9.704 1
100 100 2180 375 7.44 0.312 13.9 6.219 1
200 200 2180 645 8.89 0.402 3.96 3.548 1
400 400 2180 320 6.89 1.434 § -0.506 -0.906 1
50‡ 150 2180 966 9.56 0.178 35.5 13.77 3
100 300 2180 450 8 0.713 2.11 1.639 3
200 600 2180 612 8.78 1.072 -0.156 -0.242 3
400 1200 2180 823 9.33 1.64 -0.399 -1.238 3
† Values represent the concentration of individual drugs necessary to produce the same degree of survival as the combination treatment and were
calculated from dose response curves.
¶ Survival represents the fraction of cells viable after 48 hrs of incubation (CLS Day1) divided by the survival after a further 32 hrs of incubation.
‡ The drug combination (150 nM myriocin + 50 nM rapamycin = 60 ng/ml myriocin + 46 ng/ml rapamycin) shown in this row was used to generate the
lifespan data shown in Fig. 1A and other experiments labeled with the term ComboDT.
§ Underlined values represent drug combinations in the corresponding row that give additive or antagonistic effects.
doi:10.1371/journal.pone.0121877.t001
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TORC1 activity [12, 40]. To determine if ComboDT increases stress resistance we examined re-
sistance to oxidative (hydrogen peroxide) or heat stress on CLS day 1. ComboDT cells were
more than ten-fold resistant to heat stress than either drug alone (Fig. 1B, top panel) and such
resistance to heat stress persisted from day 1 through day 5 (Fig. 1B, bottom set of panels—
compare the 30°C control samples to the 55°C heat stressed samples). ComboDT slightly in-
creases (*2-fold) resistance to hydrogen peroxide stress compared to rapamycin alone and in-
creases resistance more than 10-fold compared to myriocin alone (Fig. 1B, top panel).
TORC1 Signaling and Stress Resistance
Because TORC1 controls aging and longevity in many organisms [1, 3, 41] including regulation
of CLS in fission yeast [12], we determined if ComboDT decreases TORC1 activity as a way to
extend lifespan. Tco89 is a nonessential core subunit of TORC1 and deletion of the tco89 gene,
which decreases TORC1 activity, enhances CLS in fission yeast similar to what is seen in WT
cells treated with rapamycin [12]. Moreover, treatment of tco89Δ cells with rapamycin does not
further increase CLS, indicating that TORC1 plays a key role in lifespan. We also find that
tco89Δ cells live longer than WT cells and that neither ComboDT nor the single drugs further
increase CLS in a statistically significant way (Fig. 2A), consistent with ComboDT enhancing
CLS by decreasing TORC1 activity. One unique feature of ComboDT is that it promotes sur-
vival of WT cells at day 5 better than does deletion of tco89, suggesting, and as we show below,
that ComboDT uses both TORC1-dependent and-independent mechanisms to enhance CLS.
Unexpectedly, when rapamycin is used alone at the low concentration contained in ComboDT
there is a small, but statistically significant reduction in the CLS of tco89Δ cells. This effect of
rapamycin was not seen previously [12] and may be due to one or more small differences in ex-
perimental protocols including glucose concentration (Rallis et al. vs. our work: 3% vs. 2%),
aeration/oxidative stress (shaker rpm 130 vs. 220), incubation temperature (32°C vs. 30°C) and
initial cell density (A600nm of 0.15 vs. 0.005).
To explore further the influence of ComboDT on the TORC1 pathway, we examined
TORC1 substrates. The S6 kinases, exemplified by the Sch9 kinase in S. cerevisiae [29, 30] and
S6K1 and S6K2 kinases in mammals [32], are one of the best characterized TORC1 substrates.
There has been debate about which S. pombe kinases are actual S6K orthologs, but at this time
they appear to be Psk1, Sck1 and Sck2 [33]. A seemingly universal function of TORC1 is to reg-
ulate protein synthesis in response to nutrients and stresses [10] and this function is achieved
in part by phosphorylation and activation of the S6 kinases, which phosphorylate substrates
such as the ribosomal protein S6 [32]. Psk1, Sck1 and Sck2 all phosphorylate the S. pombe S6
proteins Rps601 and Rps602 [12, 33].
We reasoned that if ComboDT enhances lifespan by down-regulating TORC1 activity, then
the CLS of psk1Δ cells should be lower than WT cells during drug treatment. Our data support
this hypothesis because the CLS of ComboDT-psk1Δ cells is reduced compared to ComboDT-
WT cells (Fig. 2B). However, CLS in ComboDT- psk1Δ cells is not reduced down to the level
seen in untreated WT or psk1Δ cells, which have identical lifespans (Fig. 2B), indicating that
the combination treatment is modulating other TORC1-dependent outputs or other pathways
independent of TORC1 to produce maximal effects on lifespan. Likewise, treatment with either
myriocin or rapamycin does increase the CLS of psk1Δ cells, but only to the level seen in WT
cells, indicating that ComboDT affects psk1Δ cells in ways that the individual drugs cannot do.
Examination of stress resistance in ComboDT-treated psk1Δ cells shows that they are less
resistant to heat and oxidative stress than ComboDT-treated WT cells (Fig. 2C). Since drug
treatment increases heat and oxidative stress in the absence of Psk1 function, the drugs must
be modulating additional pathways to promote stress resistance and data shown below add
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additional support to this hypothesis. Lastly, we examined the effect of ComboDT on phos-
phorylation of Myc-tagged Psk1 and the ribosomal S6 proteins Rps601/602 [Rsp6s [33]].
Myriocin by itself does not change the mobility of Psk1-13Myc nor does it change the phos-
phorylation level of Rps6s (Rsp6-P) (Fig. 2D, compare lanes 1 and 2), indicating that the drug
has no measurable effect on the TORC1 pathway. In contrast, low dose rapamycin treatment
causes Psk1-13Myc to migrate faster, representing dephosphorylation, and it eliminates the
Rps6-P signal (Fig. 2D, lane 3), as seen previously with short term, acute rapamycin treatment
[33, 40]. The same results are seen with ComboDT (Fig. 2D, lane 4) and this is probably due to
rapamycin, not the drug combination. From the data shown in Fig. 2, we conclude that Com-
boDT down-regulates the TORC1-Psk1/S6K pathway in S. pombe and that this reduction plays
a role in extending lifespan. But our data also show that the drug combination must be influ-
encing other substrates of this pathway and perhaps other signaling pathways because the
tco89Δ and psk1Δmutations do not entirely eliminate the effect of ComboDT on lifespan.
Fig 2. ComboDT requires the TORC1-Psk1 pathway to extend lifespan. (A) Effect of deleting the tco89 subunit of TORC1 on CLS in cells +/- drugs. (B)
Effect of deleting the psk1 gene, encoding an S6 kinase substrate of TORC1, on CLS. (C) Effect of deleting the psk1 gene on heat and hydrogen peroxide
stress resistance. (D) The effect of drugs on TORC1 activity was determined by measuring TORC1-mediated phosphorylation of Myc-tagged Psk1 and the
Psk1 substrate protein Rps6. Tubulin (Tub) served as a loading control for samples shown in each lane of the bottom immunoblot while the two upper blots
show the concentration of Psk1–13Myc (Myc) or phosphorylated Rps6 (Rps6-P).
doi:10.1371/journal.pone.0121877.g002
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The Sck1 and Sck2 protein kinases were also examined since they are substrates of TORC1
with roles in lifespan [21, 22, 33]. We find that the CLS of untreated sck1Δ cells is lower than
WT cells, but they do respond to ComboDT and live longer than untreated mutant cells, al-
though not as long as ComboDT-WT cells (Fig. 3A). Untreated sck2Δ cells live longer than
WT cells, similar to what others have observed [21, 22, 24]. They too respond to ComboDT
and have an enhanced CLS which, surprisingly, is higher than ComboDT-WT cells (Fig. 3A).
Finally, the CLS of untreated sck1Δ sck2Δ double mutant cells is like the sck2Δ cells, but the
CLS of the double mutant is not enhanced by ComboDT. These data point to Sck1 and Sck2 as
vital components in the mechanisms of lifespan enhancement controlled by ComboDT, with
each kinase providing unique inputs.
To show that ComboDT actually affects the Sck1 and Sck2 proteins, we examined these ki-
nases by immunoblotting as done previously [33]. We find that myriocin treatment causes a
decrease in the HA signal of HA-tagged Sck1 compared to no drug treatment, but does not af-
fect HA-Sck2. Data were quantified by measuring the ratio of the HA signal to tubulin, an in-
ternal control protein (Fig. 3B). On the other hand, rapamycin by itself decreases the HA signal
of both Sck1 and Sck2 and does so to about the same extent as does ComboDT, indicating that
the rapamycin component of the ComboDT is primarily responsible for the reduction of Sck2.
For Sck1 rapamycin may be solely responsible for the reduction in protein level, but myriocin
alone does have an effect and may contribute to the reduction seen with ComboDT (Fig. 3B).
These data suggest that ComboDT modulates CLS in part by reducing the level of the Sck1 and
Sck2 proteins to a level that allows the drugs to produce a synergistic increase in lifespan.
ComboDT Requires the PKA Pathway to Maximally Enhance Lifespan
Down-regulation of the glucose-responsive PKA pathway in S. pombe [21] as well as in S. cere-
visiae [42, 43] and mice [44] enhances lifespan. Generally, a high level of glucose activates the
PKA pathway and suppresses longevity (promotes aging) while a low level of glucose, as in
some dietary restriction protocols including in fission yeasts [23], promote longevity in ways
that are only partially understood, even in budding yeasts where this pathway has been exam-
ined in greatest detail [45–47]. To determine if the PKA pathway in S. pombe is used by Com-
boDT to enhance CLS, we examined a pka1Δmutant and matched WT strain that have been
used in previous lifespan studies [21]. As shown before, the CLS of untreated pka1Δ cells is
greatly enhanced relative to untreated WT cells but only slightly enhanced compared to Com-
boDT-WT cells (Fig. 4A). ComboDT reduces the CLS of pka1Δ cells about 10-fold (Fig. 4A)
and this is likely due to rapamycin in ComboDT, because rapamycin treatment reduces the
CLS of pka1Δ cells to about the same extent as ComboDT. Myriocin treatment has no effect on
the CLS of pka1Δ. In addition, the resistance of pka1Δ cells to heat and oxidative stress is re-
duced by rapamycin treatment or ComboDT while myriocin treatment slightly increases stress
resistance (Fig. 4B). From these data we conclude that the PKA pathway is necessary for Com-
boDT to produce its maximal effect on lifespan and heat and oxidative stress resistance. These
data also reveal that a low dose of either myriocin or rapamycin modulate lifespan and stress
resistance in distinct ways.
As another way to evaluate whether ComboDT modulates the PKA pathway, we examined
expression of the fbp1 gene, encoding fructose 1,6-bisphosphatase, a glucose-repressible en-
zyme in the gluconeogenic pathway [48]. A strain carrying an fbp1-lacZ reporter gene was used
for these assays and β-galactosidase activity was measured in cells grown in medium with 2%
glucose to repress gene expression. Neither low dose rapamycin nor myriocin derepress fbp1-
lacZ expression above the basal level seen in untreated, glucose-repressed cells (Fig. 4C). In
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Fig 3. Both Sck1 and Sck2 are required for lifespan enhancement by ComboDT. (A) The effect of drugs
on CLS are shown for WT, sck1Δ, sck2Δ and sck1Δ sck2Δ double mutant cells. (B) The effect of drugs on
TORC1-regulated phosphorylation of HA-tagged Sck1 and Sck2 was examined by immunoblotting. Numbers
below each lane indicate the ratio of the Anti-HA signal to the Anti-Tubulin signal, which served as a protein
loading control. This experiment was performed twice with duplicate cultures and similar results were
observed each time.
doi:10.1371/journal.pone.0121877.g003
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contrast, ComboDT produces a statistically significant increase in fbp1-lacZ expression, show-
ing that ComboDT down-regulates the PKA pathway even during glucose repression.
Low concentrations of glucose promote down-regulation of the PKA pathway and high ex-
pression of the fbp1-lacZ gene [48]. To determine how effective ComboDT is in down-regulat-
ing the PKA pathway compared to low glucose levels, we measured fbp1-lacZ expression in
cells gown in medium containing 0.1% glucose and 3% glycerol to fully derepress gene expres-
sion. Under these conditions, fbp1-lacZ expression is nearly 100-fold higher (data not shown)
than the value shown in Fig. 4C for untreated cells and 25-fold higher than for ComboDT cells,
both cultured with 2% glucose. Thus, ComboDT only partially down-regulates the PKA path-
way compared to the fully derepressed conditions promoted by low glucose levels, but the par-
tial decrease in PKA activity is enough to foster lifespan extension.
Because the PKA pathway is influenced by glucose, it is possible that ComboDT enhances
CLS by slowing the rate of glucose utilization or by reducing pathway activity in some other
manner. We examined the effect of ComboDT on the level of glucose in culture medium at 0,
24 and 48 hrs of incubation for WT, pka1Δ and sty1Δ cells. In all strains the concentration of
glucose at 48 hrs was very low and was not statistically different in drug-treated or untreated
cells (S4 Fig.). The residual concentration of glucose in the cultures containing pka1Δ cells was
about 2-fold higher than in the other strains, but even this concentration is very low and un-
likely to explain the influences of ComboDT on pka1Δ cells. Glucose utilization in untreated
pka1Δ and sty1Δ cells is slightly less than in WT cells at the 24 hr time point and in all strains
the effect of ComboDT is to slightly reduce glucose utilization. But these relatively small differ-
ences are erased by 48 hrs of growth and it seems unlikely that ComboDT enhances lifespan
primarily by modulating glucose utilization. Our data do not, however, rule out the possibility
that effects of ComboDT on glucose utilization or signaling contribute to enhanced lifespan.
Roles for Sty1 in Lifespan Enhancement by ComboDT
The Sty1/Spc1 MAP kinase in fission yeasts is essential for protection against a wide range of
environmental stresses [49, 50]. The protein is also necessary for CR, imposed by a low concen-
tration of glucose, to increase CLS [24]. Using the same sty1Δ andWT strains as were used to
study the effect of CR on lifespan [24], we find that sty1Δ cells treated or not treated with drugs
grow to about the same A600nm value as WT cells (S2 Fig.), however, their viability at CLS day
1 (48 hrs incubation) is reduced to about 40% below the WT value (Fig. 5A and 5B). To ac-
count for this phenotype, noted previously in mutants defective in the Wis1-Sty1-Atf1 pathway
[51, 52], and to better reveal the effect of drugs on viability, CLS data are plotted as colony
forming units/ml rather than as a fraction of the CLS day 1 value.
Viability in untreated sty1Δ cells falls less than 10-fold over the 5 day time frame of the
assay, showing that the mutant cells that manage to remain viable during entry into stationary
phase are in a metabolic state that maintains viability in stationary phase far better than occurs
in untreated WT cells, whose viability falls 10,000-fold over the 5 day assay period (Fig. 5A).
Rapamycin and ComboDT each enhance the viability of sty1Δ cells at CLS day 1 along with
lowering the loss of viability to about a 3-fold decrease (compared to*10-fold without drug
treatment) over the course of the assay whereas myriocin treatment has no effect on the viabili-
ty of sty1Δ cells.
Fig 4. The PKA pathway is vital for ComboDT to enhance CLS and stress resistance. (A) The effect of
drugs on the CLS of WT and pka1Δ cells are shown. (B) Spot-dilution (10-fold from left to right) assays show
the response of WT and pka1Δ cells from CLS day 1 to heat or hydrogen peroxide stress treatment. (C)
Influence of drugs on expression of the glucose-repressible fbp1-lacZ reporter gene are shown.
doi:10.1371/journal.pone.0121877.g004
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In contrast to the enhancing effect of rapamycin and ComboDT on the CLS of sty1Δ cells,
the drugs have little or no enhancing effect on the exceptionally low resistance of sty1Δ cells to
heat or oxidative stress (Fig. 5B), showing that Sty1 is required for resistance to such stresses,
as observed previously [49, 51–54]. Similar to the data shown in Fig. 5A, the spot dilution
Fig 5. Effects of ComboDT on the Sty1 pathway. (A) The fraction of viable sty1Δ cells at CLS day 1 is lower than in WT cells but ComboDT enhances
viability in both types of cells. (B) Sty1 function is required for stress resistance in untreated or drug-treated sty1Δ cells. (C) Effect of ComboDT on Atf1 protein
abundance in cells expressing Myc-tagged Atf1. Upper two panels are immunoblot data for Atf1 (Anti-Myc) and the tubulin (Anti-Tub) loading control. Below
each lane is the pixel density of the Anti-Myc value divided by the value for Anti-Tub. The average of the triplicate samples is shown below the individual
values. Average values are plotted in the bottom panel along with statistical significance. (D) Diagram of the signaling pathways identified in this study that
are modulated by ComboDT to increase lifespan in WT fission yeast cells. Controlling factors are listed above each pathway with ones that reduce pathway
activity indicated by blunt-ended lines and ones that increase pathway activity indicated by arrowheads. Psk1, Sck1 and Sck2 are the fission yeast orthologs
of mammalian S6 kinases and Sty1 is the ortholog of mammalian p38 MAP kinase involved in inflammatory and other stress responses. Ways in which
myriocin might affect these pathways are presented in the Discussion.
doi:10.1371/journal.pone.0121877.g005
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assays shown in the left panels of Fig. 5B (30°C, Cont) reveal that there are fewer viable sty1Δ
cells than WT cells upon entry into stationary phase.
Activation of the Sty1 pathway by environmental stresses prompts Sty1 to transpose from
the cytosol to the nucleus where it phosphorylates and activates the Atf1 transcription factor
[49, 51, 55–57]. Activation of Atf1 can be monitored by immunoblotting of Myc-tagged Atf1
[55, 57]. If ComboDT is activating the Sty1-Atf1 pathway, then the level of Atf1–12Myc pro-
tein should be higher in drug-treated than in untreated cells. We find that ComboDT does pro-
duce a statistically significant increase in Atf1-12Myc protein, indicating that ComboDT is
activating the Sty1-Atf1 pathway. These results are consistent with previous data showing that
the level of Atf1 increases during oxidative and osmotic stress [58], and are also consistent with
ComboDT inducing expression of the fbp1-lacZ reporter gene (Fig. 4C), since Atf1 promotes
fbp1+ expression [51]. In summary, the data presented in Fig. 5 show that Sty1 is necessary to
promote survival during entry into stationary phase based upon the nearly 40% loss of survival
in sty1Δ cells. ComboDT can boost survival 2 to 3-fold in sty1Δ cells, although it is still below
the level of WT cells (Fig. 5A, Day 1). ComboDT also increases the survival of sty1Δ cells over
the 5 day time span of the CLS assay, thus, the drugs are not entirely dependent on the Sty1
pathway to enhance survival, but the pathway is necessary for ComboDT to produce a syner-
gistic effect on survival.
Discussion
The data presented here demonstrate that a low dose combination of rapamycin and myriocin
produces a synergistic increase in the CLS of S. pombe cells (Fig. 1A). These results along with
our published data showing that the same drug combination promotes a synergistic increase in
the CLS of S. cerevisiae cells, support the idea that ComboDT extends lifespan by modulating
evolutionarily conserved mechanisms, since these two yeasts diverged about 330–420 million
years (Myr) ago by one estimate [59] and by 1,144 Myr years ago by another estimate [60]. Fur-
thermore, some features of fission yeasts relevant to aging and longevity including a strict re-
quirement for aerobic growth, lack of a diauxic shift and a glyoxylate cycle and the presence of
the TORC1 regulatory proteins Tsc1/2 and the Rheb GTPase are more like mammals than
budding yeasts [61]. Likewise, gene regulation through chromatin modification and RNA in-
terference in fission yeast are more related to metazoans than to budding yeasts [62]. Finally, a
recent study examined the degree to which protein-protein interactions for orthologous pro-
teins are conserved between S. cerevisiae and S. pombe [63]. This work is especially significant
to aging and longevity because of the focus on proteins involved in stress responses and signal
transduction. The results showed that protein interactions tend not to be conserved in these
two species, rather they are rewired to form new interactions, which are believed to drive diver-
gence. Such differences between budding and fission yeasts suggest that ComboDT is able to
modulate not only conserved signaling pathways, but can also exploit species-specific pathway
rewiring and consequent novel attributes to extend lifespan. Thus, it is not unreasonable to ex-
pect that ComboDT can slow aging and perhaps enhance lifespan in multicellular eukaryotes.
We identified conserved signaling pathways used by ComboDT to enhance lifespan. Be-
cause the TORC1 pathway controls aging and longevity in many organisms [1, 3, 64] and is
used by ComboDT to enhance CLS in S. cerevisiae, we hypothesized that ComboDT uses
TORC1 to control fission yeast lifespan. Our data support the hypothesis (Fig. 2A and 2D).
TORC1 phosphorylates many substrates but the S6 kinases are the ones with the best docu-
mented roles in longevity [1, 3, 41]. Examination of the three fission yeast orthologs of mam-
malian S6 kinases, Psk1, Sck1 and Sck2, [21, 22], shows that they are required for ComboDT to
enhance lifespan (Figs. 2B and 3A).
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We find that Psk1 is not needed for a normal lifespan, the first such demonstration, but is
needed for ComboDT to produce its maximal effect on CLS (Fig. 2B, yellow curve). Intriguing-
ly, our results suggest that Psk1 is not necessary to produce synergy (Fig. 2B, yellow curve),
however, a more thorough analysis will be required to prove this possibility. Immunoblotting
of Psk1-13Myc and one of its substrates, the ribosomal S6 protein, serve to verify that Com-
boDT does indeed down-regulate the Psk1 arm of the TORC1 pathway. Furthermore, this ef-
fect is caused by the rapamycin component of ComboDT (Fig. 2D). Previously a 1 hr exposure
(less than one cell division) of cells to 50 nM rapamycin did not cause a shift in the mobility of
Psk1-13Myc [33] whereas the same drug concentration causes a complete shift in our assays
(Fig. 2D). This difference is likely to result from the longer drug-exposure time (4–5 cell divi-
sions) used in our assays. It has been suggested previously that Psk1, Sck1 and Sck2 are S6-type
kinases that have partially overlapping functions (Nakashima et al. 2012). Such redundancies
may explain the normal lifespan of psk1Δ cells that we find and the apparent lack of a role in
producing synergy.
Data for the Sck1 and Sck2 kinases are informative. ComboDT increases the CLS of sck1Δ
cells almost to the degree seen in WT cells and, surprisingly, the CLS of drug-treated sck2Δ
cells is greater than WT cells (Fig. 3A). In contrast, ComboDT does not increase CLS in sck1Δ
sck2Δ double mutant cells, demonstrating that both the Sck1 and Sck2 arms of TORC1 signal-
ing are essential for ComboDT to enhance lifespan. Immunoblot analysis of Sck protein level
verified that ComboDT does reduce TORC1 activity. As with Psk1, it is the rapamycin compo-
nent of ComboDT that controls the concentration of Sck1 and Sck2, although the level of Sck1
is reduced by myriocin to about half the value bound with rapamycin (Fig. 3B).
The CLS of sck1Δ cells was found previously to be similar to WT in culture media contain
2–3% glucose [21] whereas we see a slight reduction in CLS (Fig. 3A) that may be due to small
differences in culture conditions. The enhanced CLS of sck2Δ and sck1Δ sck2Δ cells that we ob-
serve in untreated cells (Fig. 3A) has been seen previously [21, 22, 65]. The CLS of sck2Δ cells
was shown to be enhanced by deleting pka1 [21] and we observe a similar effect when sck2Δ
cells are treated with ComboDT (Fig. 3A), which, based on data shown in Fig. 4C, is likely due
to the drug combination down-regulating the Pka1 pathway. In medium with 5% glucose,
sck1Δ and sck2Δ cells have an enhanced lifespan [22], similar to what we see with ComboDT
and further study is needed to determine if the underlying mechanisms for lifespan enhance-
ment are similar.
The Pka1 pathway, along with the Sck2 pathway, were the first in fission yeasts to be shown
to regulate CLS [21] and our data implicate both pathways as vital elements in the mechanisms
used by ComboDT to enhance lifespan. Similar to previous results, the CLS of untreated pka1Δ
cells is greater than untreated WT cells (Fig. 4A). In fact, untreated pka1Δ cells survive slightly
longer than ComboDT-treated WT cells (Fig. 4A). Rapamycin alone or in ComboDT causes a
reduction in the CLS of pka1Δ cells, although cells still live significantly longer than untreated
cells (Fig. 4A), indicating that long CLS of pka1Δ cells depends on the TORC1 pathway. Similar
to the CLS data, rapamycin and ComboDT also reduce the heat and oxidative stress resistance
of pka1Δ cells (Fig. 4B). It has between suggested that Pka1 and Sck2, operating downstream of
TORC1, function in parallel pathways that control lifespan [21, 23] and our data are consistent
with such a model, particularly with data showing negative genetic interactions between mu-
tants in the two pathways [40].
Our data demonstrate that the Sty1 MAP kinase is necessary for ComboDT to modulate
growth and metabolism so that most cells remain viable upon entry into stationary phase and
continue to remain viable longer than untreated sty1Δ or WT cells (Fig. 5A). These data are
akin to the role of Sty1 in lifespan extension induced by CR [24] and they, along with our
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results for the PKA and TORC1 pathways, show that ComboDT uses several of the same path-
ways to enhance lifespan that CR uses.
Resistance to environmental stresses is often associated with longevity, but the correlation
does not always hold true in model organisms [66, 67]. A lack of correlation between longevi-
ty and oxidative stress resistance in fission yeasts is supported by studies of long-lived strains
[40] and also by our studies with ComboDT. While WT fission yeasts treated with ComboDT
are more resistant to heat and oxidative stress (Fig. 1B), these phenotypes may not be essen-
tial for increased CLS. For example, heat or hydrogen peroxide treatment strongly reduce the
viability of pka1Δ and sty1Δ cells yet CLS is enhanced by ComboDT in these mutants to a
level that far exceeds the CLS of untreated WT cells (Figs. 4A and 5A). Understanding the
mechanisms that enable ComboDT to enhance lifespan in pka1Δ and sty1Δ cells may provide
key insights into novel ways to moderate aging and promote longevity despite low stress
resistance.
Lifespan enhancement by calorie restriction or growth in a non-repressing carbon source
like glycerol [21] produce a large increase in CLS similar to what we find with ComboDT and
the underlying mechanisms may have similarities. For example, both low glucose (0.2%) [23,
48] and ComboDT (Fig. 4C) induce expression of the fbp1-lacZ reporter gene, indicative of
down-regulation of the Pka1 pathway. Likewise, both treatments increase protection against
oxidative stress produced by hydrogen peroxide treatment [23] (Fig. 1B). More similarities be-
tween the mechanisms that increase lifespan during CR or growth in a non-repressing carbon
source and ComboDT are likely to exist. Nitrogen starvation is an established way to promote
quiescence or survival during stationary phase [61]. Although we did not specifically determine
if nitrogen starvation and ComboDT work in similar ways to promote lifespan, it seems likely
that they have some features in common since both require functions of Sty1.
Results from these studies are summarized in Fig. 5D. TORC1, PKA and Sty1 are the three
pathways we have identified as being required for ComboDT to produce a synergistic increase
in CLS in WT cells. These signal transduction pathways respond to glucose other nutritional
starvation conditions along with environmental stresses such as reactive oxygen species and
high temperature, indicating that ComboDT works in part by mimicking the effects of these
types of stresses. These low level stress effects are similar to what ComboDT does to S. cerevi-
siae cells, indicating that the drugs promote mild, sub-lethal stress or hormesis as at least part
of the mechanism for increasing lifespan, similar to what is believed to occur in other longevity
promoting strategies including rapamycin treatment and dietary or calorie restriction. [68–70].
Future studies will be required to identify other signaling pathways and cellular processes
regulated by ComboDT that promote longevity. Many complex cellular processes including
cell growth and size control, protein synthesis, autophagy and other processes dependent on
membrane trafficking, along with proteostasis, nitrogen, carbon and energy metabolism, and
stress resistance are likely to respond to ComboDT. A recent systematic screen for mutants re-
sistant to TORC1 inhibition by rapamycin plus caffeine gives insight into the multifaceted
manner in which this pathway and its downstream target Sck2 respond to a drug combination
that enhances lifespan [40]. The combination of rapamycin and myriocin may produce more
complex outputs to enhance lifespan because myriocin works by lowering the rate of sphingoli-
pid synthesis and, when combined with effects of reduced TORC1 activity on other lipid bio-
synthesis pathways, has the potential to alter lipid signaling molecules, membrane trafficking,
membrane protein activity and phase transitions in membranes thereby perturbing multiple
cellular compartments [18, 71]. We speculate that such changes along with alterations in me-
tabolism coalesce to enhance lifespan.
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Material and Methods
Strains and media
S. pombe strains used in this study are listed in S1 Table. Yeast extract complete medium (YES)
contained yeast extract (5 g/L, BD, Difco), supplemented with 222 mg/L of adenine (A), uracil
(U), leucine (L) and histidine (H), and glucose (2%)[23].
CLS assay
CLS was assayed as described previously [23]. Cells grown overnight at 30°C to saturation in
YES medium, were diluted into 25 ml of medium (125 ml flask) to give an initial A600nm of
0.005. Cultures were incubated at 30°C in an air bath shaker (220 rpm) for two days (48 hrs)
and cell viability was measured (CLS day 1) by diluting and spreading cells on YES plates. Col-
onies were counted after 2–3 days of incubation at 30°C (4–5 days of incubation for slow grow-
ing pka1Δ cells) and expressed as a fraction of the day 1 value. Statistical significance was
determined by using the two-tailed Student’s t-test. For drug treatment, cells were cultured in
medium containing a final concentration of 0.29% (v/v) ethanol with or without drug(s). This
was done by first adding a calculated volume of 95% ethanol to the medium followed by dilut-
ing a stock solution of drug (50 μg Myriocin/ml or 25 μg Rapamycin/ml, both in 95% EtOH) to
give a concentration of 150 nMMyriocin (Sigma) or 50 nM Rapamycin (LC Laboratories)
or both.
Stress resistance assay
Cells were grown as described for a CLS assay in YES medium for the time indicated in
Figure legends and then diluted to give an A600nm of 1.0 units/ml followed by treatment with
hydrogen peroxide for 60 min at room temperature with mixing. Serially diluted (10-fold) cells
were spotted (4 μl) onto YES plates and incubated at 30°C for 2–3 days. For heat stress resis-
tance, cells were serially diluted (10-fold dilution starting with an A600nm = 1), spotted onto
YES plates, and incubated at either 55°C (heat-shocked) or 30°C (control) for 60 or 90 min, fol-
lowed by incubation for 2–3 days at 30°C.
Protein extraction and western blotting
Cells were grown as described for a CLS assay and cell-free yeast extracts were prepared by
using a modified published procedure [58]. Briefly, 20 A600nm units of cells, grown from 0.005
to 1.0 A600nm with or without drug(s), were slowly combined with cold 50% trichloroacetic
acid to give a final concentration of 6% followed by incubation on ice for 5 min and then cen-
trifugation for 5 min x 5,000 g. Pellets were washed once with cold water, suspend in 1 ml of
0.2 N NaOH, transferred to a screw-capped microfuge tube and incubated for 5 min at room
temperature before centrifugation. Pellets were suspended in sample buffer (0.06 M Tris-HCl,
pH 6.8, 5% glycerol, 2% SDS, 1mM EDTA) at a concentration of 10 A600nm units per 100 μl.
Samples were heated at 95°C for 8 min, centrifuged and the protein concentration of the super-
natant was determined by using the DC protein assay kit (Bio-Rad Laboratories). Samples
electrophoresed on SDS-PAGE gel were transferred onto a PVDF membrane (Millipore Immo-
bilon-FL) by using a Bio-Rad semi-dry transfer system. Membrane blocking and antibody
binding were done in TBST (20 mM Tris, 150 mMNaCl, 0.1% Tween-20, pH 7.5) containing
5% nonfat dry milk. Primary antibodies were anti-Myc tag (1:2000, Millipore, clone 9E10, Cat.
#05–419), anti-phospho-(Ser/Thr) Akt substrate (1:1000, Cell signaling, Cat.#9611), anti-HA
tag (1:2000, Sigma, Cat.#H6908) and anti-tubulin (1:2000, Sigma, Cat.#T5168). Second anti-
bodies were anti-Mouse IgG (1:5000, Sigma, Cat.#A3562) or anti-Rabbit IgG (1:5000, Sigma,
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Cat.#A3687). Fluorescent signals from membranes exposed to an ECF substrate (Amersham
Biosciences) were analyzed by using the Bio-Rad ChemiDoc MP Imaging System and quanti-
fied by using the Image Lab Software.
β-Galactosidase assay
β-galactosidase activity was measured in cells grown to log phase (A600nm = 1.0). Cells were col-
lected by centrifugation and suspended in 1 ml of Z buffer (0.06 M Na2HPO4, 0.04 M
NaH2PO4, 0.01 M KCl, 0.001 MMgSO4, pH 7.0, 0.05 M β-mercaptoethanol (add fresh)). Cells
were made permeable by adding 25 μl chloroform and 40 μl 0.1% SDS followed by vortexing.
β-galactosidase activity was expressed as nmol/min/mg protein. Statistical analysis was per-
formed by using a two-tailed Student’s t-test.
Supporting Information
S1 Fig. Effect of individual drugs on cell growth.WT S. pombe cells were diluted into culture
medium containing the indicated concentration of myriocin (Myr, Panel A) or rapamycin
(Rap, Panel B) and grown as described for a CLS assay. Absorbance at 600nm (A600 nm) was
measured at the indicated times. Average values for three cultures are show. [100 ng/ml Myr =
250 nM and 10 ng/ml Rap = 10.86 nM].
(PDF)
S2 Fig. Effect of ComboDT on cell growth.WT, pka1Δ and sty1Δ cells were diluted into cul-
ture medium +/- ComboDT (50 nMmyriocin + 150 nM rapamycin = 60 ng/ml myriocin + 46
ng/ml rapamycin) and grown as described for a CLS assay. Absorbance at 600nm (A600 nm)
was measured at the indicated times. Average values for three cultures are show.
(PDF)
S3 Fig. Determination of EC50 for individual drugs. (A) EC50 of individual myriocin treat-
ment. Cells were grown as described in a CLS assay for 48 hrs, and survival in a serial dilution
series of myriocin (0, 62.25, 124.5, 249, 498, 747, 996, 1494 nM) was measured at a fixed time
(time 0, CLS day 1, 100% survival) and again after 32 hrs. The effect of myriocin treatment on
survival at 32 hrs was assessed to obtain the median effective concentration (EC50). Nonlinear
regression was used to fit the survival versus concentration curve. (B) EC50 for rapamycin
treatment. Concentrations of rapamycin are 0, 32.7, 109, 218, 545, 1090, 2180 nM.
(PDF)
S4 Fig. Glucose utilization during the first 48 hrs of culture incubation. (A) The concentra-
tion of glucose was measured in triplicate cultures of WT, pka1Δ and sty1Δ cells at the time of
inoculation (0 hrs) and after 24 and 48 hrs of incubation at 30°C. Glucose was measured by
using a commercial kit (Glucose Oxidase-Catalase Assay, Shanghai Rongsheng Biotech Co.
Ltd, China. Cat.: 361500). (B) Average numerical values for the data plotted in A are shown
along with statistical evaluation of the indicated comparisons made by using the Students’ t-
test.
(PDF)
S1 Table. Strains used in this study.
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S2 Table. Statistical analysis of CLS data.
(XLSX)
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